Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
BMC Cancer. 2017 Feb 8;17(1):117. doi: 10.1186/s12885-017-3106-y.
Chemokine (C-C motif) ligand 17 (CCL17) is a chemokine mainly produced by myeloid dendritic cells. It is a ligand for CC chemokine receptor 4 (CCR4) and CC chemokine receptor 8 (CCR8). The aim of this study was to investigate prognostic values of CCL17 expression in patients with clear cell renal cell carcinoma (ccRCC).
The study included 286 patients with ccRCC. CCL17 expression was analyzed by immunohistochemistry on tissue microarrays. Prognostic values of CCL17 expression and patients' clinical outcomes were evaluated.
Kaplan-Meier method showed that low CCL17 expression was associated with worse patient overall survival (OS) and recurrence-free survival (RFS) (OS, P = 0.002; RFS, P = 0.007). Low CCL17 expression was an adverse independent risk factor for OS and RFS in multivariate analyses (OS, P = 0.006, P = 0.011 for bootstrap; RFS, P = 0.002, P = 0.025 for bootstrap). We constructed two nomograms incorporating parameters derived from multivariate analyses to predict patients' OS and RFS (OS, c-index 0.799; RFS, c-index 0.787) and they performed better than existed integrated models.
Low CCL17 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with ccRCC after nephrectomy. Established nomograms based on this information could help predict ccRCC patients' OS and RFS.
趋化因子（C-C 基序）配体 17（CCL17）是一种主要由髓样树突状细胞产生的趋化因子。它是 CC 趋化因子受体 4（CCR4）和 CC 趋化因子受体 8（CCR8）的配体。本研究旨在探讨 CCL17 表达在透明细胞肾细胞癌（ccRCC）患者中的预后价值。
本研究纳入了 286 例 ccRCC 患者。通过组织微阵列的免疫组织化学分析 CCL17 表达。评估 CCL17 表达和患者临床结局的预后价值。
Kaplan-Meier 方法表明，低 CCL17 表达与患者总生存（OS）和无复发生存（RFS）较差相关（OS，P=0.002；RFS，P=0.007）。在多变量分析中，低 CCL17 表达是 OS 和 RFS 的不良独立危险因素（OS，P=0.006，P=0.011 用于自举；RFS，P=0.002，P=0.025 用于自举）。我们构建了两个包含多变量分析中得出的参数的列线图，以预测患者的 OS 和 RFS（OS，c-index 0.799；RFS，c-index 0.787），它们的性能优于现有的综合模型。
低 CCL17 表达是肾切除术后 ccRCC 患者复发和生存的潜在独立不良预后生物标志物。基于该信息建立的列线图可以帮助预测 ccRCC 患者的 OS 和 RFS。
